OLMEDOXLATA

This brand name is authorized in Estonia

Active ingredients

The drug OLMEDOXLATA contains one active pharmaceutical ingredient (API):

1 Olmesartan medoxomil
UNII 6M97XTV3HD - OLMESARTAN MEDOXOMIL

Olmesartan medoxomil is a potent, orally active, selective angiotensin II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations.

Read about Olmesartan medoxomil

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C09CA08 Olmesartan medoxomil C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09C Angiotensin II antagonists, plain → C09CA Angiotensin II antagonists, plain
Discover more medicines within C09CA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1616734, 1616745, 1616756, 1616767, 1616778, 1616789, 1616790, 1616802, 1616813, 1616824, 1616835, 1616846, 1616857, 1616868, 1616879, 1616880, 1616891, 1616903, 1616914, 1616925, 1616936, 1616947, 1616958, 1616969, 1616970, 1616981, 1616992, 1617005, 1617016, 1617027, 1617038, 1617049, 1617050, 1617061, 1617072, 1617083, 1617094, 1617106, 1617117, 1617128, 1617139, 1617140, 1617151, 1617162

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈